The Drug Enterprise in the Age of AI
AI is speeding up the search for new medicines. Can it make the discoveries themselves?…
The Drug Enterprise in the Age of AI
AI is speeding up the search for new medicines. Can it make the discoveries themselves? Few people are better placed to answer than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don’t exist in nature, and…
Science FTW
By KIM BELLARD Science won. At least, that’s one of the takeaways from last week’s midterm elections. If you were one of the 124 million Americans who voted, you probably already know that there was a Blue Wave, with resounding Democrat victories across the country, even in historically red areas. Georgia not only reelected its…
Amy Bucher, Lirio Health
Lirio Health is an interesting under-the-radar company, which works with plans, providers and others to try to influence the behavior of their members and patients. Of course, everybody wants to change the behavior of human beings, and it’s been proven over the years to be very hard. Lirio probably has more PhDs per square foot…
Startup Supporting Caregivers Raises $3.5M in Seed Funding
Avanlee Care’s seed round was led by BEA Venture Fund, with participation from existing investors, including Board Chair Esther Dyson, Chrysalis Ventures and FairBridge VC. The post Startup Supporting Caregivers Raises $3.5M in Seed Funding appeared first on MedCity News.
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now. The post Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health” appeared…
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies. The post Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition appeared first on MedCity News.
At the Helm of eHealth Exchange, Doug Dietzman Eyes New Use Cases for Data Sharing
Organization’s new president says one area of focus will by CMS’ new requirements for payers
Simulation-Guided Clinical Trials: Is EU Law Ready?
Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor….
AI and the Future of Revenue Cycle Management
Upcoming Healthcare Innovation webinar explores how health systems can use AI to improve financial performance, streamline operations, and reduce administrative burden.
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that reset the immune system to treat autoimmune disease. The post Nkarta Autoimmune…
